Resveratrol: spectacular in mice, disappointing in humans

Resveratrol is the molecule that launched the modern longevity-supplement industry — the compound in red wine that supposedly mimics caloric restriction and switches on the “longevity gene.” Two decades later, it’s also the clearest cautionary tale in the field: a molecule with genuinely spectacular animal data and genuinely disappointing human results. Holding both is the whole point.

The origin of the hype

The story started in 2003, when researchers reported that resveratrol activated the sirtuin SIRT1 and extended yeast lifespan by 70%, framing it as a chemical mimic of caloric restriction.^[1] Then a 2006 Nature paper found resveratrol improved the health and survival of mice on a high-calorie diet, shifting their physiology toward that of lean mice and opposing the diet’s effects in 144 of 153 metabolic pathways; it also noted lifespan extension across yeast, worms and flies.^[2] These were striking, legitimately exciting results — and they are all in yeast, invertebrates, or high-calorie-fed rodents. No human longevity claim was ever supported.

What happened in humans: not much

When resveratrol was actually tested in people, the spectacular effect evaporated. A meta-analysis of 11 randomized trials (388 subjects) concluded resveratrol improves glucose control and insulin sensitivity in people with diabetes — but has no effect on glucose measures in non-diabetics.^[3] A second meta-analysis quantified the diabetic benefit as a small fasting-glucose reduction (about 0.29 mmol/L) with negligible change in HbA1c — i.e., a modest, population-restricted effect, not the metabolic transformation the mouse data implied.^[4] For healthy people taking it as an anti-aging supplement, the controlled human evidence shows essentially nothing.

The exercise red flag

More than just “didn’t help,” one well-run trial found resveratrol could hurt. In healthy older men doing high-intensity exercise training, adding 250 mg of resveratrol daily blunted the cardiovascular benefits of the exercise: the placebo group’s improvement in maximal oxygen uptake was 45% greater than the resveratrol group’s, and only placebo saw a drop in blood pressure.^[5] Tellingly, SIRT1 protein levels weren’t even affected — the proposed mechanism didn’t engage.^[5] For anyone who exercises, that’s a reason for real caution, not just indifference.

Why it fails to translate: bioavailability

A big part of the explanation is pharmacokinetics. A human tracer study found that while resveratrol is well absorbed, it’s metabolized so fast that only trace amounts of the intact molecule (under 5 ng/mL) ever reach the bloodstream — its systemic bioavailability is “very low.”^[6] The compound that works in a dish barely exists in your blood after you swallow it, which is a plausible reason the dramatic lab effects don’t carry over.

Safety

Resveratrol is generally well tolerated, but two cautions matter: high doses (2.5 g/day and up) cause mild-to-moderate GI symptoms,^[7] and at 1 g/day it meaningfully inhibits the drug-metabolizing enzymes CYP3A4, CYP2D6 and CYP2C9 — a real interaction risk for anyone on common medications (many statins, blood thinners, antidepressants) cleared by those enzymes.^[8]

The honest bottom line

Resveratrol’s preclinical record is genuinely impressive and its human record is genuinely underwhelming — modest benefit in diabetics, nothing in healthy people, a negative interaction with exercise, and near-zero bioavailability to explain the gap.^[3][5][6]It’s the molecule that taught the field to distrust “extends lifespan in yeast” headlines. If you want the cellular-energy pathway resveratrol was supposed to influence, the better- evidenced route is NAD+ precursors; for other longevity compounds held to the same standard, see quercetin and spermidine.